Trends in Emergency Department Visits for Children, 2016-2023.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 42617794.
- Also identified by DOI 10.1016/j.jpeds.2026.115286.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To evaluate longitudinal changes in diagnoses related to emergency department (ED) utilization and associated costs among children in US EDs. We performed a serial cross-sectional study using the 2016-2023 Nationwide Emergency Department Sample, a nationally representative all-payor ED sample. We evaluated longitudinal changes in diagnoses (using the Diagnosis Grouping System) and costs (inflation adjusted 2023 dollars) over time overall utilizing negative binomial regression and log-linear regression, respectively. We then performed interrupted time-series analyses to account for the onset of the COVID-19 pandemic in 2020. We identified 198,256,299 ED encounters. Overall trends shifted by diagnosis, with increases in psychiatric/behavioral diseases and substance abuse (+2.8% annually; 95% CI, 1.2, 4.4) and endocrine/metabolic/nutritional diseases (+3.7%; 95% CI, 0.4, 7.2). Several diagnoses declined, including skin/soft tissue disease (-9.0%; 95% CI, -13.0, -4.8), urinary tract disease (-4.9%; 95% CI, -7.1, -2.7), and trauma (-4.6%; 95% CI, -7.1, -2.1). In time series analyses, the COVID-19 pandemic was associated with sharp declines in encounters, followed by post-pandemic increases, especially for eye disease (+27.8% annually; 95% CI, 21.5, 34.5), ear, nose and throat (ENT), dental/mouth disease (+20.0%; 95% CI, 15.4, 24.7), fluid/electrolyte disorders (+19.7%; 95% CI, 13.9, 25.7), and respiratory disease (+18.7%; 95% CI, 6.2, 32.6). Inflation-adjusted costs increased in psychiatric/behavioral diseases and substance abuse (+10.6%; 95% CI, 8.2, 12.9), systemic states (+9.5%; 95% CI, 3.9, 15.3), and endocrine/metabolic/nutritional diseases (+6.3%; 95% CI, 0.7, 12.3). Post-pandemic cost increase was greatest for ENT/dental/mouth disease (+24.6%; 95% CI, 16.9, 32.7), eye disease (+24.1%; 95% CI, 15.3, 33.6), and psychiatric/behavioral diseases and substance abuse (+12.1%; 95% CI, 5.1, 19.6). We identified changes in ED presentations and costs over time, with notable changes for psychiatric/behavioral and substance abuse conditions. These findings have implications for health systems and policymakers amid major shifts in ED use over the past decade.